The Global Health Body Issues Concern Over Severe Shortage of Weight-Loss Medications

Fewer than one in 10 individuals that would benefit from obesity jabs including Wegovy can access them, caution the WHO as it issues its initial guidance on the drugs.

With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.

Per forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The latest guidance affirms that excess weight is a lifelong illness that can be addressed with thorough and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are key barriers to broad access to the jabs that can aid individuals in losing substantial body mass, notes the agency.

Skinny Jab Shortage

Despite the current most optimistic case, the production of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, according to the WHO.

The guideline calls on countries and companies to increase availability, by approaches such as licensing agreements.

Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in multiple countries in 2026.

The Way Weight-Loss Injections Function

These medications mimick a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so users consume fewer calories.

Patients typically begin shedding pounds within a few weeks of starting on the regular doses.

Evidence points to users may put most of the weight back on within a year of stopping the drug, because their usual appetite return.

To be above a healthy weight increases your chance for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.

Excess weight affects people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.